Altimmune Shares Are Trading Higher On Expanded Manufacturing Pact With Lonza

Altimmune Inc (NASDAQ: ALThas expanded its previously-announced manufacturing collaboration with Lonza Group LZAGY for AdCOVID, its single-dose intranasal COVID-19 vaccine candidate.

  • Under the expansion, Lonza will commission a dedicated manufacturing suite for clinical and commercial production of AdCOVID, at its facility near Houston, Texas.  
  • In December, the FDA issued a clinical hold on Altimmune's investigational New Drug application for AdCOVID. The agency requested certain protocol modifications and the submission of additional chemistry, manufacturing, and controls data. 
  • The recently commenced Phase 1 study with data readout is expected in the second quarter of 2021.
  • Price Action: ALT shares gained 19.7% at $20.20 in the premarket trading on the last check Friday.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: BiotechNewsHealth CareContractsSmall CapFDAGeneralCOVID-19 VaccinePhase 1 Trial
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!